Receptos Inc. (RCPT) Is Up Sharply On Phase 2 Study Results

By RTT News, 
A A A


(RTTNews.com) - Receptos Inc. ( RCPT ) announced after the bell Monday that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis met the primary endpoint of reduction in MRI brain lesion activity.

Receptos gapped open sharply higher Tuesday morning and is now up 9.59 at $38.79 on above average volume. The stock has jumped to a month and a half high.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com



This article appears in: News Headlines

Referenced Stocks: RCPT

RTT News


More from RTT News:

Related Videos

Stocks

Referenced

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM